RTM receives marketing authorisation for Fludeoxyglucose (18F)

We are happy to announce that RTM has received marketing authorization for ¹⁸F-FDG of 17 July 2018.

Fludeoxyglucose (¹⁸F) RTM 200 MBq/ml, solution for injection will become commercially available in The Netherlands in October, with roll-out to Belgium and Germany planned in 2019.

Other news

Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers

Klaudia Cybulska (postdoc radiochemistry) has written an article about Huntington's Disease. Abstra...

1st production QuiremSpheres

On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the s...

GMP-certificate received

Today we received our GMP-certificate!The results of the inspection were excellent and no shortcomin...

First liver cancer patient treated with microspheres irradiated in TU Delft

Radboud Translational Medicine will perform the dispensing of below product. The production and dis...

News